Will Canafenib be included in medical insurance in 2025? Latest progress in medical insurance negotiations

As of2025, Encorafenib has not been officially approved for marketing in mainland China, and therefore has not been included in the National Medical Insurance Drug List. At present, if domestic patients want to use the drug, they usually need to rely on overseas channels to obtain the original version of the drug, mainly from Europe, the United States or some countries and regions in Asia. As the regulatory approval process is still in the advanced stage, there is still great uncertainty as to whether canafenib will be included in medical insurance in 2025, which depends on the progress of the registration review by the National Medical Products Administration (NMPA) and the progress of medical insurance negotiations.

As a BRAF inhibitorCanafenib has been approved in European and American countries for the treatment of patients with metastatic BRAF V600E mutations melanoma, colorectal cancer, non-small cell lung cancer (NSCLC) and other patients. Its efficacy and safety have been verified in multiple clinical trials, especially in combination with cetuximab in the treatment of metastatic colorectal cancer, significantly extending patient survival and improving quality of life. Therefore, the potential market for this drug in China is very broad in the future.

Judging from the trend of medical insurance inclusion, the country has attached great importance to the accessibility of innovative targeted drugs in recent years, especially for cancer types with specific mutation targets and urgent treatment needs. Drugs with significant clinical benefits are more likely to receive priority review and medical insurance support. If canafenib successfully completes registration approval and passes price negotiations in 2025, its possibility of entering the medical insurance directory will be greatly increased. However, even if it is included in medical insurance in the future, it will usually be limited to patients who have tested positive for the BRAF V600E mutation, meet specific disease types and treatment lines, and must meet the corresponding conditions for reimbursement by the medical insurance fund.

Therefore, when choosing canafenib treatment, patients should first evaluate its indications and gene mutation status, and pay close attention to the latest developments released by the National Food and Drug Administration and the National Medical Insurance Bureau. If the drug cannot be obtained through formal channels in the short term, the safety and rationality of overseas drug use can be evaluated under the guidance of a doctor to avoid blind use of drugs or delay in treatment opportunities.

Reference materials:https://www.braftovi.com/